Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

WHO naming of forazapadin formalizes Satellos’ lead program as it advances multiple Phase 2 trials in Duchenne muscular dystrophy.

Rhea-AI Summary

Satellos Bioscience (MSLE) received the World Health Organization-assigned International Nonproprietary Name “forazapadin” for its lead oral small molecule drug, previously known as SAT-3247.

The company said this naming milestone supports ongoing and future regulatory and commercialization plans for Duchenne muscular dystrophy (DMD). Forazapadin is being studied in two Phase 2 DMD trials: BASECAMP, a global randomized, placebo-controlled study in pediatric participants, and TRAILHEAD, an open-label study in adults. Satellos expects BASECAMP enrollment to complete this quarter and BASECAMP clinical data to be released in the fourth quarter, and intends to start a Phase 2 trial in facioscapulohumeral muscular dystrophy by the end of 2026.

Positive

• WHO-assigned INN forazapadin formalizes identity of lead DMD candidate
• Forazapadin in two Phase 2 DMD trials: BASECAMP (pediatric) and TRAILHEAD (adult)
• Company expects BASECAMP enrollment completion this quarter
• Company expects to report BASECAMP clinical data in Q4
• Intends to initiate Phase 2 trial in FSHD by end of 2026

Negative

• None.

News Explained

The WHO-assigned International Nonproprietary Name changes the drug candidate’s public name from SAT-3247 to forazapadin; Satellos expects to use the new name more broadly in future scientific, regulatory and corporate communications.

Argus 15 min delay

+4.08% vs previous close $9.55 last price 0.5x rel. volume Open Argus

Details

Market Reaction – MSLE

$9.16 $9.72 Day Range

$202.72M Market Cap

Following this news, MSLE has gained 4.08%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $9.55.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The July 8 TRAILHEAD data event carried a reported 9.38% 24-hour reaction and involved the same prog...

Analysis

The July 8 TRAILHEAD data event carried a reported 9.38% 24-hour reaction and involved the same program now renamed forazapadin; this announcement reported nomenclature, not new clinical results.

Key Figures

Phase 2 DMD studies: 2 Phase 2 studies FSHD trial timing: By the end of 2026 BASECAMP enrollment: This quarter +1 more

Phase 2 DMD studies

2 Phase 2 studies

Forazapadin in Duchenne muscular dystrophy

FSHD trial timing

By the end of 2026

Planned Phase 2 trial initiation

BASECAMP enrollment

This quarter

Expected enrollment completion

BASECAMP data timing

Fourth quarter

Expected clinical data release

Historical Context

2 past events · Latest: Jul 08

2 events

1. Jul 08

   TRAILHEAD clinical data

   24h Move

   +9.4%

   Six-month interim data reported for the SAT-3247 Duchenne program

2. Jun 29

   FDA Fast Track designation

   24h Move

   +11.4%

   FDA granted Fast Track designation for SAT-3247 in Duchenne

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

international nonproprietary name, small molecule, aak1, phase 2, +1 more

5 terms

international nonproprietary name regulatory

"assignment of the International Nonproprietary Name (INN)"

International nonproprietary name (INN) is the official generic name assigned to an active pharmaceutical substance that is recognized worldwide and distinct from company brand names. Investors care because an INN creates a common label for comparing products, tracking regulatory approvals, and measuring market demand and competition—like a universal model number that prevents confusion between different brands and helps assess commercial prospects.

small molecule technical

"orally administered, small molecule drug candidate"

A small molecule is a low-weight chemical compound that can enter cells easily and interact with specific proteins or biological pathways to change how they work, much like a small key fitting into a lock. Investors care because small molecules are a common and often faster route to develop medicines, can be manufactured at scale, and may offer clearer regulatory and commercial paths compared with larger biologic therapies, affecting potential costs, timelines and returns.

aak1 medical

"Forazapadin targets AAK1, a key protein"

AAK1 is a human gene that makes a protein acting like a traffic controller inside cells, helping move and sort molecules into and out of the cell. Investors care because drugs that block or modify AAK1 can change how cells handle infections or neurological signals, so evidence that a therapy affects AAK1 can influence the value of biotech pipelines, clinical trial prospects, and future regulatory or commercial outcomes.

phase 2 medical

"currently being evaluated in two Phase 2 studies"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

placebo-controlled medical

"a global, randomized, placebo-controlled study"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced the assignment of the International Nonproprietary Name (INN) “forazapadin” for the Company's orally administered, small molecule drug candidate designed to restore muscle regeneration that was previously known as SAT-3247.

“As we continue to execute our clinical development strategies, this naming designation reflects the maturity of the program and supports its future development as we plan for regulatory submission and commercialization in Duchenne muscular dystrophy,” said Frank Gleeson, co-founder and chief executive officer of Satellos. “Importantly, it comes amid a period of significant momentum across our Duchenne clinical programs, notably the expected completion of enrollment this quarter in the BASECAMP study and the release of clinical data from the BASECAMP study, which is expected in the fourth quarter.”

The INN, assigned through the World Health Organization naming process, establishes a globally recognized, nonproprietary name for the therapy as forazapadin advances through clinical development and toward potential commercialization. Forazapadin is currently being evaluated in two Phase 2 studies in patients with Duchenne muscular dystrophy (DMD) and the company intends to begin a Phase 2 clinical trial in facioscapulohumeral muscular dystrophy (FSHD) by the end of 2026.

ABOUT FORAZAPADIN

Forazapadin is a proprietary, oral, small molecule drug candidate being developed by Satellos as a novel approach to regenerating skeletal muscle lost in DMD and other degenerative muscle diseases or injury conditions. Forazapadin targets AAK1, a key protein identified by Satellos as capable of helping restore the body’s natural muscle repair and regeneration biology, a fundamental process that is disrupted in DMD and other degenerative conditions. By inhibiting AAK1, forazapadin treatment aims to re-establish a biochemical signal needed to support muscle regeneration. Satellos is advancing forazapadin as a potential treatment for DMD that is independent of dystrophin and applicable regardless of exon mutation status as either a stand-alone or adjunctive therapy, with ongoing Phase 2 clinical studies including BASECAMP, a global, randomized, placebo-controlled study in pediatric participants, and TRAILHEAD, an open-label study in adult participants.

The Company previously referred to the program as SAT-3247 and expects to transition to broader use of the INN in future scientific, regulatory and corporate communications.

ABOUT SATELLOS BIOSCIENCE INC.

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed forazapadin, an orally administered small molecule AAK1 inhibitor designed to address deficits in muscle repair and regeneration. Forazapadin is being evaluated as a potential disease-modifying treatment, for DMD in two Phase 2 clinical trials, BASECAMP in pediatric participants with DMD and TRAILHEAD in adults living with DMD, as well as for FSHD. The Company has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com and connect with Satellos on X, LinkedIn, Facebook and Instagram.

NOTICE ON FORWARD-LOOKING STATEMENTS

This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the possibility of pursuing regulatory approval for forazapadin, the potential for forazapadin to represent a disease modifying approach to the therapeutic treatment of people living with DMD; anticipated benefits to patients from a small molecule treatment for DMD; the enrollment in, advancement and timing of results of forazapadin through clinical trials, including the BASECAMP and TRAILHEAD clinical trials; the pharmacodynamic properties and mechanism-of-action of forazapadin; the potential of our approach in other degenerative muscle diseases and Satellos’ plans to pursue additional muscle diseases and injury conditions in future clinical development; forazapadin's prospective impact on DMD patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally, including whether results observed in the TRAILHEAD study will continue to mature or will translate to the pediatric population studied in BASECAMP; the anticipated timing for an Investigational New Drug submission to the U.S. Food and Drug Administration for forazapadin for evaluation in facioscapulohumeral muscular dystrophy and the anticipated timing for the launch of a related Phase 2 clinical trial; Satellos' technologies and drug development plans; and the company’s expectations regarding the sufficiency of its cash, cash equivalents and short-term investments to fund operations, including its expectation that its current cash resources will provide a runway through 2027. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often, but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective”, “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. These statements are based on assumptions and subject to risks and uncertainties. In making forward looking statements, the Company has relied on various assumptions, including but not limited to: its ability to obtain future funding on favorable terms, if at all; obtaining positive results in its clinical trials, its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks and uncertainties described in more detail in the “Risk Factors” section of Satellos' Annual Information Form dated March 27, 2026, and amended and restated short form base shelf prospectus dated August 11, 2026 (each of which is located on Satellos' SEDAR+ profile) and incorporated by reference in Satellos’ Form F-10 filed with the Securities and Exchange Commission on August 11, 2026, and in Satellos' public filings on EDGAR (sec.gov) and SEDAR+ (sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.

CONTACTS

Investors: Caitlin Lowie, Vice President, Investor Relations & Communications, ir@satellos.com

Media: Emily Williams, Senior Director, Communications, media@satellos.com

FAQ

What is forazapadin and how does it work?

Forazapadin is a proprietary, orally administered small molecule drug candidate being developed to regenerate skeletal muscle lost in DMD and other degenerative muscle diseases or injury conditions. It inhibits AAK1, a protein identified by Satellos as capable of helping restore the body’s natural muscle repair and regeneration biology. By inhibiting AAK1, forazapadin treatment aims to re-establish a biochemical signal needed to support muscle regeneration.

How is forazapadin positioned for use in Duchenne muscular dystrophy patients?

Satellos is advancing forazapadin as a potential treatment for Duchenne muscular dystrophy that is independent of dystrophin and applicable regardless of exon mutation status. It is being developed as either a stand-alone therapy or an adjunctive treatment, with ongoing Phase 2 trials in both pediatric participants (BASECAMP) and adults (TRAILHEAD) living with DMD.

What future development plans beyond DMD does Satellos have for forazapadin?

Forazapadin is planned for evaluation in facioscapulohumeral muscular dystrophy (FSHD), with the company intending to begin a Phase 2 clinical trial by the end of 2026. Satellos has also identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these in future clinical development.

What is the significance of receiving an International Nonproprietary Name (INN)?

The INN “forazapadin”, assigned through the World Health Organization naming process, establishes a globally recognized, nonproprietary name for the therapy. The company said this designation reflects the maturity of the program and supports its future development as it plans for regulatory submission and potential commercialization in Duchenne muscular dystrophy.